5 Best Small-Cap Healthcare Stocks To Buy Now

4. Arvinas, Inc. (NASDAQ:ARVN)

Number of Hedge Fund Holders: 22

Market Capitalization as of December 12: $1.945 Billion

Arvinas, Inc. (NASDAQ:ARVN) is a Connecticut-based clinical-stage biopharmaceutical company that is engaged in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. On November 22, Arvinas, Inc. (NASDAQ:ARVN) announced early results from its Phase 2 cohort expansion portion of a Phase 1/2 study for protein degrader ARV-471 it co-develops with Pfizer Inc. (NYSE:PFE), indicating a clinical benefit rate of 38% among breast cancer patients. 

On December 5, investment advisory Citi maintained a Buy recommendation on Arvinas, Inc. (NASDAQ:ARVN) but lowered the price target on Arvinas, Inc. (NASDAQ:ARVN) to $72 from $88. Analyst Yigal Nochomovitz issued the ratings update. 

According to Insider Monkey’s data, 22 hedge funds were bullish on Arvinas, Inc. (NASDAQ:ARVN) at the end of the third quarter of 2022, with combined stakes worth $445.8 million, compared to 21 funds in the prior quarter worth $374.5 million. David Witzke and Michael Gregory’s Avidity Partners Management is the biggest position holder in the company, with 4.3 million shares worth $193.2 million. 

Follow Arvinas Inc. (NASDAQ:ARVN)